Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...

Pre-earnings options volume in Rani Therapeutics (RANI) Holdings is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 12.6%, or 30c, after results ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today ...

Investing.com - Rani Therapeutics Holdings (NASDAQ: RANI) reported third quarter EPS of $-0.36, $0.07 better than the analyst estimate of $-0.43. Revenue for the quarter came in ...

The stock price of Rani Therapeutics Holdings Inc (NASDAQ: RANI) has plunged by -5.17 when compared to previous closing price of 2.51, but the company has seen a 3.04% gain in its stock price over the ...

After hours: November 13 at 6:34 PM EST Loading Chart for RANI ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Owens & Minor, Inc.-15.74%-30.19% ...

Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase... Likelihood of Approval and Phase Transition Success ...

Rani Mukherjee is an Indian film actress and is considered as one of the most successful and high profile actresses in Bollywood. She made her Bollywood debut in 1996 with the movie Raja Ki Aayegi ...